WuXiBody is a novel bispecific antibody (bsAb) platform developed by WuXi Biologics. Its key feature is the replacement of one parental antibody's CH1/CL constant region with the T cell receptor (TCR) constant domain, a design aimed at promoting cognate heavy chain (HC)-light chain (LC) pairing. BsAbs based on WuXiBody can adopt either asymmetric or symmetric format. LC-missing species, a byproduct frequently associated with bsAb containing sequence engineered Fab arm, is also identified during WuXiBody production. Nevertheless, WuXiBody's unique design greatly facilitates removal of this type of impurity, which can otherwise be difficult to clear. In this work, with two concrete cases (WuXiBodies with asymmetric and symmetric designs, respectively), we showed that Capto MMC ImpRes mixed-mode chromatography can effectively remove LC-missing byproducts as well as aggregates, demonstrating that this resin is a powerful tool for WuXiBody purification.

WuXiBody是由WuXi Biologics开发的新型双特异性抗体（bsAb）平台。它的关键特征是用T细胞受体（TCR）恒定域替换一个亲本抗体的CH1 / CL恒定区，该设计旨在促进同源重链（HC）-轻链（LC）配对。基于WuXiBody的BsAb可以采用非对称或对称格式。在WuXiBody的生产过程中，也发现了缺少LC的物种，这是一种经常与含有序列工程化Fab臂的bsAb相关的副产物。尽管如此，WuXiBody的独特设计极大地促进了这种杂质的清除，否则这些杂质很难清除。在这项工作中，有两个具体案例（分别具有非对称和对称设计的WuXiBodies），